Last week, Australia's Therapeutic Goods Administration (TGA) approved the weight-loss drug Mounjaro to treat sleep apnea, a condition in which breathing stops and starts repeatedly during sleep.

Zepbound was approved last year to treat obesity. The drug's maker, Eli Lilly, says it reduces the severity of obstructive sleep apnea by 63%.

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Do those on Zepbound have to switch to Wegovy after Caremark drops Zepbound from preferred coverage? What options are there?

GLP-1 medications offer promising benefits for obesity and diabetes patients, with studies showing reduced heart attack risk and potential applications for addiction treatment.

Some individuals living with obesity and overweight may find it difficult to embark on a weight loss journey alone. It’s not ...

New data from a Phase 3 trial show that the daily anti-obesity pill may be as safe and effective as drugs like Mounjaro and Ozempic for weight loss and lowering blood sugar.

Last week, Australia's Therapeutic Goods Administration (TGA) approved the weight-loss drug Mounjaro to treat sleep apnea, a condition in which breathing stops and starts repeatedly during sleep.

Last week, Australia’s Therapeutic Goods Administration (TGA) approved the weight-loss drug Mounjaro to treat sleep apnoea, a ...